While Sarepta News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from While sarepta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In While Sarepta Today - Breaking & Trending Today
Dive Brief: Sarepta Therapeutics has disclosed positive data from a small trial of a drug meant to be a more potent successor to its marketed Duchenne muscular dystrophy treatment Exondys 51, announcing Monday the experimental drug resulted in stronger production of a key muscle-building protein that Duchenne patients lack. Sarepta reported a worrisome side effect alongside treatment, however. Reduced magnesium levels, which can lead to heart damage and seizures, were observed in two of the four patients Sarepta reported data from. Executives said the side effect went away after the patients received oral magnesium, and believe that such supplements can keep the condition from occurring in the future. ....
Share this article Share this article NEW YORK, Feb. 4, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ( Sarepta or the Company )(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On January 7, 2021, Sarepta issued a press release announcing top-line results for Part 1 of the Company s Study SRP-9001-102 ( Study 102 ), an ongoing, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in 41 patients with Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to m ....